Want to join the conversation?
$CELG said overall survival, a key secondary endpoint, showed no benefit with REVLIMID. Based on these results, $CELG does not currently plan to seek approval for this. REMARC evaluated maintenance therapy with REVLIMID versus placebo in diffuse large B-cell lymphoma patients on first-line rituximab plus CHOP chemotherapy induction therapy.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!